Ehave Expands Dashboard Capabilities to Include Decentralized Trials and Virtual Studies

Licensing agreement with Health Wizz allows Ehave to enter medical records management and retrieval; sets the stage to administer remote digital therapeutics.

MIAMI, June 02, 2021 (GLOBE NEWSWIRE) — Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients, today announced the expansion of its Dashboard capabilities to include data management platform technologies which allow digitally captured information, like electronic health records (EHRs) to be shared. Under the terms of the licensing agreement with Health Wizz, Ehave will offer its dashboard users medical records management and retrieval through a dedicated instance on the AWS (Amazon Web Services) platform. This takes the Ehave dashboard to a new level by providing a HIPAA compliant, decentralized mobile platform that enables people to aggregate, organize and share personal medical health records securely and efficiently.

Ehave will be able to engage with patients remotely through a series of milestones on their phones. Health Wizz deliverables to Ehave include an Ehave branded mobile app on the App Stores, as well as a HIPAA compliant dedicated backend and web portal to engage with patients. The Ehave partnership with Health Wizz will enable people to download, aggregate, and standardize all of their health records on their mobile phones. This advanced technology will provide data integrity and patient privacy while allowing people to share their medical data with medical providers, research organizations, and pharmaceutical companies conducting clinical trials. The Health Wizz mobile platform leverages blockchain technology to provide consumers with the tools they need to aggregate, manage and share their medical data with stakeholders, including research organizations and pharmaceutical companies, all while ensuring data integrity and protecting patient’s privacy.

“Ehave is going to revolutionize how you manage and connect your health data through our platforms making it easier to a path to a clearer and healthier you,” said Alfred Farrington, Chief Information Officer of Ehave.

Nitin Desai, MD, President and Chief Medical Officer of Health Wizz commented, “We are very excited to see our technology partnership with Ehave leverage our platform for a much needed, rapidly expanding area in disease management, especially targeting mental health with innovative use of Psychedelics. Health Wizz has a secure, robust back end coupled with a very user-friendly, patient-facing and patient-centric mobile front-end.”

The healthcare industry lacks comprehensive, easy-to-use tools and systems that allow individuals to own and share their health data in a secure and private environment. Health Wizz has developed a platform to leverage blockchain, data management and mobile technologies that shift the locus of control from medical institutions back to the patient, which enables people to take control of their own data.

“We are excited to partner with Ehave to bring unprecedented efficiencies when conducting medical research and trials remotely. The pandemic has raised the urgency to interact with participants remotely on their mobile devices. Use of blockchain will provide data integrity for medical records that are aggregated from various sources while also verifying data provenance,” said Raj Sharma, Chief Executive Officer of Health Wizz.

Data Collected Directly From Patients

The Ehave Dashboard utilizing the blockchain based data management platform solution developed by Health Wizz will collect health data directly from patients, including genomic data and wearables data. Below are a few of the highlights:

  1. Ehave can use the Health Wizz web application to recruit participants with an invitation to participate in a screening survey.
  2. Members that opt in to participate in trials provide complete medical histories, enabling targeted recruitment and to ensure accuracy of data.
  3. ‘Smart Contracts’ on Ethereum blockchain reward trial participants with redeemable “OMP” tokens for each milestone completed by the participant.

The Ehave Dashboard is a data driven platform that has been strategically developed to provide better communication among patients, medical practitioners, and health care providers. The aggregation of data and information into one application has proven effective in streamlining the health process for both patients and providers. The cloud based platform can deliver critical features and capabilities to healthcare providers, all while enabling seamless integrations with everything from electronic health records (EHRs) to telehealth providers to psychedelic researchers and clinicians. The Ehave Dashboard has been developed through years of testing with mental healthcare professionals at one of Canada’s largest hospitals. In addition to providing better outcomes, the proprietary platform allows individuals to take control of their physical and mental health. 2020 marked a first for our Company as our data platform allowed patients to access innovative treatments to mental health by providing clinicians and pharmaceutical companies with data that will make the provision of care more readily available.

“We are very pleased to work with Health Wizz to add its blockchain based data management platform solution over the Amazon Web Service cloud to our Ehave Dashboard,” said Ben Kaplan, Chief Executive officer of Ehave. “Blockchain can play an important role in making virtual clinical trials a reality when coordination among stakeholders is critical for data-sharing. This partnership marks our entry into the medical records management and retrieval space and could potentially propel Ehave into a leadership position in clinical trials and medical passports.”

The global EHR market is expected to reach $33.41 billion by 2025. Even though the market boasts huge numbers, the adoption of EHR has had many problems, such as data breaches, scalability, interoperability and data integration. The mobile platform developed by Health Wizz addresses these problems by returning ownership of medical health records back to the consumer.

Mr. Kaplan said, “We believe people must be in control of their health records. It is their body and their data.”

About Ehave, Inc.

Ehave, Inc. (EHVVF) is a leader of digital therapeutics delivering evidence-based therapeutic interventions to patients. Our primary focus is on improving the standard care in therapeutics to prevent or treat brain disorders or diseases through the use of digital therapeutics, independently or together, with medications, devices, and other therapies to optimize patient care and health outcomes. Our main product is the Ehave Telemetry Portal, which is a mental health informatics platform that allows clinicians to make objective and intelligent decisions through data insights. The Ehave Infinity Portal offers a powerful machine learning and artificial intelligence platform with a growing set of advanced tools and applications developed by Ehave and its leading partners. This empowers patients, healthcare providers, and payers to address a wide range of conditions through high quality, safe, and effective data-driven involvement with intelligent and accessible tools. Additional information on Ehave can be found on the Company’s website at: www.ehave.com.

About Health Wizz

Health Wizz is a secure mobile platform that provides consumers with the necessary tools for aggregating, organizing, and sharing their medical health records over the blockchain. Founded in 2016, Health Wizz is on a mission to empower consumers with the necessary tools to better manage their health and medical records.

For more information on Health Wizz, please visit www.healthwizz.com.

Forward-Looking Statement Disclaimer

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the Company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company’s products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company’s industry and introduction of competing products; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading “Risk Factors” in Ehave, Inc.’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC’s website, http://www.sec.gov.

Ehave KetaDASH Subsidiary Commences Data Collection for Potential Patients and Partnering Clinics

Brings Ketamine treatments for anxiety, depression and PTSD to the home; Supports Ketamine clinics and mental health professionals.

MIAMI, May 20, 2021 (GLOBE NEWSWIRE) — Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today its KetaDASH subsidiary has commenced data collection for potential patients and partnering clinics. KetaDASH, which is a HIPAA compliant, cloud based platform, will be first to market as a home healthcare provider offering IV based infusion therapy of ketamine. KetaDASH is available to ketamine clinics and qualified patients whose healthcare provider has prescribed it as a treatment. Qualified patients, doctors, and clinics are invited to visit https://www.ketadash.com/sign-up/ for more information.

KetaDASH has designed a smart and intuitive dashboard that provides qualified patients and medical professionals detailed insight to medical data. Qualified patients can easily create a profile, check availability of the medical professionals, and schedule appointments through a proprietary app on a smart phone. The KetaDASH platform utilizes proprietary software developed by Ehave which allows patients and medical professionals to view detailed reports on the ketamine therapy’s progress. The KetaDASH platform will also include staffing, medical and legal protocols, and equipment. More information on KetaDASH is available at www.ketadash.com.

Ketamine therapy has turned out to be a life-changing alternative to antidepressants for many patients. Ketamine has been used since the 1960s as an anesthesia. In lower doses, ketamine has proven effective to ease pain, which means people could need fewer addictive painkillers. Researchers have concluded ketamine can also help those suffering from treatment-resistant depression, which is mainly found in people who have tried other treatments with little, or no, success. The FDA has not approved ketamine for that use, but some mental health professionals are prescribing ketamine to their patients who have this type of depression. People with severe depression typically get ketamine either through an IV or a nasal mist about once a week, in a clinic under strict medical supervision. In some patients, ketamine can ease symptoms of depression in just a few hours. In some studies, 85 percent of the people who tried ketamine benefitted from improved mental health. In March 2019 the U.S. Food and Drug Administration approved Spravato (esketamine) nasal spray, in conjunction with an oral antidepressant, for the treatment of depression in adults who have tried other antidepressant medicines but have not benefited from them (treatment-resistant depression). Esketamine is the s-enantiomer of ketamine. Ketamine is a mixture of two enantiomers and was approved by the FDA in 1970. The FDA granted the approval of Spravato to Janssen Pharmaceuticals, Inc., a pharmaceutical company headquartered in Beerse, Belgium and owned by Johnson & Johnson. Ketamine clinics are now available in most major cities. Canadian based Field Trip Health currently has six locations providing ketamine treatments in Toronto, New York, LA, Chicago, Atlanta and Houston, and six more under construction in Amsterdam, San Diego, San Carlos, Seattle, Washington DC and Fredericton, New Brunswick.

“Pioneering ketamine treatments in a homecare setting is an outstanding opportunity to offer an enhanced and much-needed mental health service for patients who otherwise might not be in a position to otherwise receive care,” said Ehave CEO, Ben Kaplan. “We look forward to bringing compassion and comfort, as well as setting the standard for a high-quality level of care, to patients and their families who will benefit from ketamine treatments.”

Ehave’s KetaDASH platform allows ketamine clinics to extend their services to the home in order to provide access to ketamine treatments for those in need. KetaDASH will partner with existing ketamine clinics to help them gather patients for treatment by matching patients with the best facilities for treatment of their mental health diagnosis. KetaDASH provides Ehave the opportunity to build a revenue producing platform while providing potentially lifesaving Ketamine infusion therapy for the treatment of psychiatric disorders, such as major depressive disorder, bipolar disorder, and post-traumatic stress disorder. KetaDASH is available to ketamine clinics and qualified patients whose healthcare provider has prescribed it as a treatment. Qualified patients, doctors, and clinics are invited to visit http://www.KetaDash.com/sign-up for more information.

Additional Ehave Inc. Information

We are truly grateful for the support of EHVVF shareholders! Please join the conversation on our Ehave supporter’s telegram group at https://t.me/EhaveInc.

The company posts important information and updates through weekly videos from the official company YouTube channel https://www.youtube.com/channel/UCnyW1mgMd0qmYkEMq3O6FWA.

Please follow Ehave on Twitter @Ehaveinc1

About Ehave, Inc.

Ehave, Inc. (EHVVF) is a leader of digital therapeutics delivering evidence-based therapeutic interventions to patients. Our primary focus is on improving the standard care in therapeutics to prevent or treat brain disorders or diseases through the use of digital therapeutics, independently or together, with medications, devices, and other therapies to optimize patient care and health outcomes. Our main product is the Ehave Telemetry Portal, which is a mental health informatics platform that allows clinicians to make objective and intelligent decisions through data insights. The Ehave Infinity Portal offers a powerful machine learning and artificial intelligence platform with a growing set of advanced tools and applications developed by Ehave and its leading partners. This empowers patients, healthcare providers, and payers to address a wide range of conditions through high quality, safe, and effective data-driven involvement with intelligent and accessible tools. Additional information on Ehave can be found on the Company’s website at: www.ehave.com.

Forward-Looking Statement Disclaimer

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the Company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company’s products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company’s industry and introduction of competing products; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading “Risk Factors” in Ehave, Inc.’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC’s website, http://www.sec.gov.

Ehave Prepares to Launch Ketamine Clinical Trials Using Brain Scientific’s Brain Mapping Technology

Ehave will partner with Brain Scientific Inc. to leverage both data and AI to correlate biomarkers for the Identification of Chronic pain, Depression (major and persistent), PTSD, Bipolar disorder, General anxiety, ADHD and Schizophrenia

MIAMI, April 16, 2021 (GLOBE NEWSWIRE) — Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today plans to launch brain mapping ketamine clinical trials using Brain Scientific technology later this year. The clinical trial will establish the statistical correlation between the ketamine treatment and patient improvement from the disorders.

The trial, which is designed to enroll 35 patients, is expected to start in the second half of 2021. Ehave is currently completing the necessary preclinical studies necessary to begin enrolling patients in the trial. The average drop out ratio of clinical trials is around 15 % and Ehave will need at least 25-30 patients’ egg data to establish statistical significance of the efficacy of the ketamine over the indication, such as PTSD and Major Refractory Depression. Ehave will partner with Brain Scientific Inc. to leverage both data and AI to correlate biomarkers for the Identification of Chronic pain, Depression (major and persistent), PTSD, Bipolar disorder, General anxiety, ADHD and Schizophrenia. The two companies will collaborate to exploit graph based AI, linked data protocols with respect to such AI and leverage such data and AI to develop neural net algorithms.

Ketamine has been used in the past to reduce the amount of potentially addictive pain medication required after certain medical procedures, but it is now being studied as a treatment for major depression, though it has not yet been approved by the FDA to treat depression. In March 2019 the U.S. Food and Drug Administration approved Spravato (esketamine) nasal spray, in conjunction with an oral antidepressant, for the treatment of depression in adults who have tried other antidepressant medicines but have not benefited from them (treatment-resistant depression). Esketamine is the s-enantiomer of ketamine. Ketamine is a mixture of two enantiomers and was approved by the FDA in 1970. The FDA granted the approval of Spravato to Janssen Pharmaceuticals, Inc., a pharmaceutical company headquartered in Beerse, Belgium and owned by Johnson & Johnson. Ketamine clinks to treat depression are becoming common in many cities in the U. S. and Canada. Ehave intends to provide Ketamine clinics and medical practitioners with software, staffing, protocols, and equipment as part of the KetaDASH platform.

Dr. Manideep Gopishetty, Medical Advisor and Chief Medical Officer of Ehave said, “The brain mapping of the patients to measure the efficacy of the ketamine treatment would help us to identify the biomarkers of the brain which shows the changes in neuroplasticity of the brain areas impacted by the treatment and could pave pathway to new forms of treatment using the drug and would also help companies to bring ketamine treatment to fore front to address chronic mental health disorders based on the outcomes of the study.”

The study’s primary goal is to assess the candidate therapy’s safety and tolerability. Both Ehave and Brain Scientific have expressed a commitment to provide regular progress updates regarding the clinical trial process, activities related to the study’s launch, and any expected timelines. Depression is a common mental disorder affecting more than 264 million people worldwide. Mental health experts find a strong link between loneliness and depression and drug overdoses. According to national drug abuse data, drug overdoses have increased 42% since Covid-19 reared its ugly head. As a result, mental health disorders are on the rise in every country and could cost the global economy up to $16 trillion annually by 2030.

Alfred Farrington II, CIO of Ehave, Inc. said, “Ehave’s goal is to help practitioners make more informed decision about mental health care. We believe the data from this clinical trial will provide longitudinal insights that can link brain analysis and psychedelics. This clinical trial in conjunction with Brain Scientific has the potential to revolutionize mental health by digitizing and analyzing data in order to give the health industry the opportunity to learn from it and help mental health researchers make informed decisions for better outcomes.”

Ben Kaplan, CEO of Ehave said, “We are very grateful to all families who volunteer to take part in research and drug development efforts. We look forward to continuing our remarkable partnership with Brain Scientific as we advance towards a treatment for major depression.”

Additional Ehave Inc. Information

We are truly grateful for the support of EHVVF shareholders! Please join the conversation on our Ehave supporter’s telegram group at https://t.me/EhaveInc.

The company posts important information and updates through weekly videos from the official company YouTube channel https://www.youtube.com/channel/UCnyW1mgMd0qmYkEMq3O6FWA.

Please follow Ehave on Twitter @Ehaveinc1

About Ehave, Inc.

Ehave, Inc. (EHVVF) is a leader of digital therapeutics delivering evidence-based therapeutic interventions to patients. Our primary focus is on improving the standard care in therapeutics to prevent or treat brain disorders or diseases through the use of digital therapeutics, independently or together, with medications, devices, and other therapies to optimize patient care and health outcomes. Our main product is the Ehave Telemetry Portal, which is a mental health informatics platform that allows clinicians to make objective and intelligent decisions through data insights. The Ehave Infinity Portal offers a powerful machine learning and artificial intelligence platform with a growing set of advanced tools and applications developed by Ehave and its leading partners. This empowers patients, healthcare providers, and payers to address a wide range of conditions through high quality, safe, and effective data-driven involvement with intelligent and accessible tools. Additional information on Ehave can be found on the Company’s website at: www.ehave.com.

About Brain Scientific:

Brain Scientific is a commercial-stage healthcare company with two FDA-cleared products, providing next-gen solutions to the neurology market. The Company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. To learn more about our corporate strategy, devices or for investor relations please visit: www.brainscientific.com or email us at info@memorymd.com.

Forward-Looking Statement Disclaimer

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the Company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company’s products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company’s industry and introduction of competing products; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading “Risk Factors” in Ehave, Inc.’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC’s website, http://www.sec.gov.